Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients.
Acitretin
/ administration & dosage
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
/ etiology
Cross-Over Studies
Female
Humans
Keratinocytes
/ pathology
Keratolytic Agents
/ administration & dosage
Male
Middle Aged
Organ Transplantation
/ adverse effects
Postoperative Complications
/ etiology
Retrospective Studies
Secondary Prevention
Skin Neoplasms
/ etiology
Treatment Outcome
Basal cell carcinoma
Chemoprevention
Keratinocyte carcinoma
Nonmelanoma skin cancer
Retinoids
Squamous cell carcinoma
Transplant recipients
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
12
2020
accepted:
24
02
2021
pubmed:
27
4
2021
medline:
26
2
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation. Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs. This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010-2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period. The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, -53% p = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma. This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation.
OBJECTIVE
OBJECTIVE
Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs.
METHODS
METHODS
This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010-2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period.
RESULTS
RESULTS
The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, -53% p = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma.
CONCLUSION
CONCLUSIONS
This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.
Identifiants
pubmed: 33902035
pii: 000515496
doi: 10.1159/000515496
doi:
Substances chimiques
Keratolytic Agents
0
Acitretin
LCH760E9T7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-166Informations de copyright
© 2021 S. Karger AG, Basel.